- Home
- NUS vs KIO Comparison
NUS vs KIO Comparison
Compare NUS & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUS | KIO |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.0M | 470.1M |
| IPO Year | 1996 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NUS | KIO |
|---|---|---|
| Price | $7.60 | $11.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 580.7K | 252.5K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ 207.80 | N/A |
| EPS | ★ 3.18 | N/A |
| Revenue | ★ $3,176,718,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | $2.40 | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $5.32 | $10.69 |
| 52 Week High | $14.62 | $12.83 |
Technical Indicators
Market Signals| Indicator | NUS | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 27.14 | 23.73 |
| Support Level | $7.30 | N/A |
| Resistance Level | $7.68 | $12.15 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 18.15 | 19.49 |
Price Performance
Historical ComparisonAbout NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.